Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease-Reference-Cited by-同舟云学术

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease

Published:2021-09-16 Issue:4 Volume:2 Page:757-764
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Abdallah Al‐Ola¹^ORCID,Mohyuddin Ghulam Rehman²^ORCID,Ahmed Nausheen¹,Mohan Meera³^ORCID,Cui Wei⁴,Shune Leyla¹,Mahmoudjafari Zahra²,McGuirk Joseph¹,Ganguly Siddhartha¹,Atrash Shebli⁵

Affiliation:

1. Division of Hematologic Malignancies & Cellular Therapeutics University of Kansas Medical Center Westwood Kansas USA

2. University of Kansas Medical Center Kansas City Kansas USA

3. Division of Hematology/Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

4. Division of Pathology & Laboratory Medicine University of Kansas Medical Center Kansas City Kansas USA

5. Levine Cancer Institute Carolinas Healthcare System Charlotte North Carolina USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.275

Reference35 articles.

1. Myeloma as a model for the process of metastasis: implications for therapy

2. Multiple myeloma

3. Extramedullary multiple myeloma

4. Extramedullary multiple myeloma

5. Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis;Clinical Lymphoma Myeloma and Leukemia;2023-04

2. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease;Journal of Hematology & Oncology;2022-10-23